Mylan Pays $9M To Settle Paclitaxel Patent Suit

Law360, New York (July 6, 2004, 12:00 AM EDT) -- Mylan Laboratories has agreed to pay $9 million to Tapestry Pharmaceuticals Inc. and Australia-based Mayne Group Ltd's U.S. unit to settle a patent lawsuit over the cancer treatment paclitaxel.

Mylan, the largest maker of generic drugs in the U.S., said the payment will end a lawsuit pending in federal court in Pittsburgh. Under the settlement, Mylan will have a paid-up license to sell paclitaxel under Mayne's patents.

“The parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western District...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.